Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov​.

Improving treatment of Burkitt's lymphoma and saving children's lives

November / December 2012 | Volume 11, Issue 6

Burkitt's lymphoma is a particularly cruel disease, hitting mostly children and developing aggressively. It is endemic in equatorial Africa, where chronic malaria helps weaken the immune system, and although chemotherapy can cure up to half of patients, many still die. So it was welcome news that an international team of scientists has unveiled some of the cancer's genetic secrets, making this form of non-Hodgkin's lymphoma easier to treat. Their findings were published recently in Nature.

Dr. Louis M. Staudt of the NIH's National Cancer Institute and his colleagues conducted genetic sequencing with high-capacity technology, which allowed them to quickly identify likely mutations that may cause the lymphoma. They found a surprisingly large amount of recurrent mutations compared with the number identified in other cancers. This opens many doors for improved understanding and potential treatments of Burkitt's lymphoma.

"Our job in cancer genomics is to divide cancer into precisely defined molecular categories," Staudt said. "That will enable a much more rapid understanding of essential pathways that could be responsive to drugs."

He noted that more effective treatments for Burkitt's lymphoma are needed especially in Africa. Patients there typically receive low-dose chemotherapy, rather than the high-dose therapies in the developed world where follow-up care is available for resulting infections. The low-dose regimen leaves a survival rate of below 50 percent. "That's way too low a rate," Dr. Staudt said. "So we hope that we might be able to supplement that minimal chemotherapy with some of these new targeted agents and improve the outcomes for patients there."

New therapies would also help the 15 percent of developed-world patients who are not treated adequately with current therapies, he noted. This includes the elderly, who are more vulnerable to infections after high-dose chemotherapy, even with ample supportive care.

More Information

• Read the related November 13, 2013 NIH news release NIH study finds low-intensity therapy for Burkitt lymphoma is highly effective.
• Read the article A Conversation with Dr. Louis Staudt about Targeting New Treatments for Burkitt Lymphoma from the September 4, 2012 issue of the National Cancer Institute Cancer Bulletin.
• Access details on the publication of Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics from PubMed.

To view Adobe PDF files, download current, free accessible plug-ins from Adobe's website.